ClinicalTrials.gg
RecruitingNCT06011408Updated Mar 12, 2024

Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes

An interventional study of TDtect in Tardive Dyskinesia, sponsored by iRxReminder. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by iRxReminder · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Tardive Dyskinesia with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Tardive Dyskinesia · United States.

Planned enrollment
2nd of 27
300 · median 89
Started
2023
with 1 other
No phase
2 of 31
1 open now
Registered
26th of 31
by date
Lead sponsor
1 of 31
iRxReminder

Among the 31 studies in Tardive Dyskinesia with a site in United States, this one is the 2nd largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 with no phase, and was the 26th registered.

Tardive Dyskinesia

62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.

Browse Tardive Dyskinesia studies →

Open to participants now

6 of the 31 studies in Tardive Dyskinesia with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Tardive Dyskinesia with a site in United States, or all of them as a file.
02

Study summary

The study is being conducted to validate the feasibility of remote assessment of Tardive Dyskinesia.

Read the detailed description

The study is being conducted to validate the feasibility of remote assessment of Tardive Dyskinesia. Participants will all be taking an antipsychotic medication and half will have a diagnosis of Tardive Dyskinesia and half will not. Participant responses to interview questions and elements of the Abnormal Involuntary Movement Scale will be collected on video. The videos will be rated by trained observers. Machine learning methods will be used to develop an algorithm to detect abnormal movements in individuals with a known Tardive Dyskinesia diagnosis. The trained rater results will be compared to the algorithm to determine the accuracy of the algorithm.

03

Conditions studied

  • Tardive Dyskinesia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For the non-TD group:

  1. Prescribed and taking an antipsychotic medication for 90-days or longer.
  2. Tardive Dyskinesia symptoms if present are not from Parkinsons, Tourette's syndrome, Huntington disease.
  3. Signed an .
  4. Speaks English fluently.

Exclusion criteria

Exclusion Criteria:

  1. Suffered a moderate or severe head injury in the last year;
  2. History of a learning disorder or developmental disability that would inhibit a patient from completing the TD protocol.
  3. Severe visual impairment that is cannot be corrected by glasses or contacts.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Other
    Taking antipsychotic medication with Tardive Dyskinesia

    Other: TDtect

  • Other
    Taking antipsychotic medication without Tardive Dyskinesia

    Other: TDtect

Interventions

  • OtherTDtect

    Collecting video data on abnormal movement

06

What researchers measure

Primary outcomes

  1. AIMS Score

    Abnormal Involuntary Scale Score

    Time frame: Baseline

07

Study locations

2 of 2 sites recruiting
  • Fermata Helath
    Brooklyn, New York 10038, United States
    Recruiting
  • Charak Research Center
    Garfield Heights, Ohio 44125, United States
    Recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for Nov 2024, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2023
First posted
Aug 25, 2023
StartActual
May 30, 2023
Primary completionEst.
Nov 30, 2024
CompletionEst.
Dec 31, 2024
Last update
Mar 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06011408
Lead sponsor
iRxReminder
Responsible party
Sponsor
First posted
Aug 25, 2023
Start date
May 30, 2023
Primary completion
Nov 30, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Mar 12, 2024

Study contacts

Anthony Sterns, Ph.D.
Contact
asterns@irxreminder.com
3306066675
Fred Ma, M.D., Ph.D.
Contact
fma@irxreminder.com
2164695725
Rakesh Ranjan, M.D.
study director · Charak Research Center
Owen Muir, M.D.
study director · Fermata Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion